Filing Details
- Accession Number:
- 0001171520-22-000489
- Form Type:
- 13D Filing
- Publication Date:
- 2022-10-06 20:00:00
- Filed By:
- Singer Julian D.
- Company:
- Gyre Therapeutics Inc. (NASDAQ:GYRE)
- Filing Date:
- 2022-10-07
- SEC Url:
- 13D Filing
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| JDS1 | 0 | 1,082,400 | 0 | 1,082,400 | 1,082,400 | 3.44% |
| CCUR Holdings, Inc | 0 | 491,700 | 0 | 491,700 | 491,700 | 1.56% |
| CIDM II | 0 | 491,700 | 0 | 491,700 | 491,700 | 1.56% |
| Julian D. Singer | 0 | 1,082,400 | 0 | 1,082,400 | 1,082,400 | 3.44% |
| David S. Oros | 388,600 | 0 | 388,600 | 0 | 388,600 | 1.2 % |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13D/A
(Rule 13d-101)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a)
(Amendment No. 18)[1]
| Catalyst Biosciences, Inc. |
| (Name of Issuer) |
| Common Stock, par value $0.001 per share |
| (Title of Class of Securities) |
| 14888D208 |
| (CUSIP Number) |
|
JULIAN D. SINGER JDS1, LLC 2200 Fletcher Avenue, Suite 501 Fort Lee, New Jersey 07024
(201) 592-3400 |
| (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) |
| October 4, 2022 |
| (Date of Event which Requires Filing of this Statement) |
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box